Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Epileptic Encephalopathy

    Current Location

    Search
    Epileptic Encephalopathy
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Clinical Trials near Blue Bell, PA

    Top Clinical Trials near Columbus, GA

    16 Glaucoma Trials near Ventura, CA

    Top Clinical Trials near Frederick, MD

    Top Breast Cancer Clinical Trials near Baltimore, MD

    216 Clinical Trials near Alabaster, AL

    Top Breast Cancer Clinical Trials near Philadelphia, PA

    Top Polycystic Kidney Disease Clinical Trials

    88 Breast Cancer Trials near New York, NY

    Top Clinical Trials near New York

    27 Eczema Trials near Tampa, FL

    Top Metastatic Breast Cancer Clinical Trials

    By Trial

    Functional MRI for Urinary Incontinence

    Tele-Palliative Care for Graft-versus-Host Disease

    Tamsulosin for Urinary Retention

    Pembrolizumab + Vorinostat for Lung Cancer

    Mobile App for Nephrotic Syndrome Management

    Talazoparib + Radiation for Gynecologic Cancers

    Lithium for Mild Cognitive Impairment

    PET/MRI for Prostate Cancer

    TMS for Cerebellar Ataxia

    Acthar Gel for Sarcoidosis

    TATE + PD-1 Inhibitor for Liver Cancer

    Faith in Action! Church-based Navigation for Breast Cancer Screening

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      21 Epileptic Encephalopathy Trials Near You

      Power is an online platform that helps thousands of Epileptic Encephalopathy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      LP352 for Epilepsy

      Columbus, Ohio
      This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:2 - 65

      Key Eligibility Criteria

      Disqualifiers:Dravet Syndrome, Neurodegenerative Disorders, Others
      Must Be Taking:Antiseizure Medications

      320 Participants Needed

      LP352 for Epilepsy

      Columbus, Ohio
      This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:2 - 66

      Key Eligibility Criteria

      Disqualifiers:Neurologic, Psychiatric, Cardiovascular, Others
      Must Be Taking:LP352

      324 Participants Needed

      Zorevunersen for Dravet Syndrome

      Columbus, Ohio
      The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:2 - 17

      Key Eligibility Criteria

      Disqualifiers:SCN1A Gain-of-function, Neuromodulation, Others
      Must Be Taking:Anti-seizure Medications

      150 Participants Needed

      LP352 for Dravet Syndrome

      Columbus, Ohio
      This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:2 - 65

      Key Eligibility Criteria

      Disqualifiers:Infantile Spasms, Neurodegenerative Disorders, Others
      Must Be Taking:Antiseizure Medications

      160 Participants Needed

      NBI-827104 for Epilepsy

      Cleveland, Ohio
      The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:4 - 12

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      24 Participants Needed

      Fenfluramine for Dravet and Lennox-Gastaut Syndromes

      Cleveland, Ohio
      This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:2+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      412 Participants Needed

      STK-001 for Dravet Syndrome

      Ann Arbor, Michigan
      This trial is testing the safety of STK-001, a new treatment for Dravet syndrome. It aims to help patients by increasing a brain protein that is usually low in this condition. The study focuses on patients who have already tried this treatment in earlier studies.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Unstable Medical Conditions, Others
      Must Not Be Taking:Sodium Channel Blockers

      60 Participants Needed

      Elsunersen for Epileptic Encephalopathy

      Chicago, Illinois
      A Randomized, Multi-Center, Double-Blind, Sham-Procedure-Controlled Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:1 - 18

      Key Eligibility Criteria

      Disqualifiers:Other Genetic Variants, Bone Disorders, Others

      50 Participants Needed

      NBI-921352 for Epilepsy

      Chicago, Illinois
      The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
      Stay on current meds

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:2 - 21

      Key Eligibility Criteria

      Disqualifiers:Dravet Syndrome, Head Trauma, Others
      Must Be Taking:Antiseizure Medications

      52 Participants Needed

      ETX101 for Dravet Syndrome

      Chicago, Illinois
      ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1) and aged ≥6 to \<48 months (Part 2). Part 1 follows an open-label, dose-escalation design, and Part 2 is a randomized, double-blind, sham delayed-treatment control, dose-selection study.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:6 - 47

      Key Eligibility Criteria

      Disqualifiers:Genetic Mutation, CNS Abnormality, Others
      Must Be Taking:Antiseizure Medications

      22 Participants Needed

      PRAX-562 for Epilepsy

      Chicago, Illinois
      This is a Phase 2, double-blind, randomized clinical trial to explore the safety, tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric participants who have seizures associated with early-onset SCN2A-DEE and SCN8A-DEE.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:2 - 18

      Key Eligibility Criteria

      Disqualifiers:Other Genetic Variants, Status Epilepticus, Others
      Must Not Be Taking:Sodium Channel Blockers

      100 Participants Needed

      Fluoxetine for Genetic Disorder

      Toronto, Ontario
      This is a single patient study of oral powdered fluoxetine to target developmental outcomes in a child with KCNC1-related disorder. This trial will be conducted at Holland Bloorview Kids Rehabilitation Hospital over 32 to 42 weeks, using a quasi experimental ABA phase design (placebo-fluoxetine-placebo) with randomized and blinded active treatment start and stop moments.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:< 18

      Key Eligibility Criteria

      Disqualifiers:Hypersensitivity To Fluoxetine, Long QT, Others
      Must Not Be Taking:MAOIs, SSRIs, Tricyclics, Others

      1 Participants Needed

      NBI-921352 for Developmental and Epileptic Encephalopathy Syndrome

      Washington D.C., District of Columbia
      Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:2 - 22

      Key Eligibility Criteria

      Disqualifiers:Dravet Syndrome, Head Trauma, Others
      Must Be Taking:Antiseizure Medications

      8 Participants Needed

      Relutrigine for Epilepsy

      Chevy Chase, Maryland
      A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:2 - 65

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Status Epilepticus, Pregnancy, Others

      160 Participants Needed

      Pediatric Palliative Care for Rare Diseases

      Washington D.C., District of Columbia
      The palliative care needs of family caregivers of children with rare diseases and their children are largely unmet, including the need for support to prepare for future medical decision making. This trial will test the FACE-Rare intervention to see if investigators can identify and meet those needs; and if FACE-Rare effects family caregivers' quality of life and child healthcare utilization. Finally, investigators will determine if the intersectionality of child-sex, family-race, Federal poverty level, and social connection influences family quality of life and child health care utilization longitudinally.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:12 - 99

      Key Eligibility Criteria

      Disqualifiers:Homicidal, Suicidal, Psychotic

      480 Participants Needed

      Gene Therapy for Developmental Encephalopathy

      Philadelphia, Pennsylvania
      The goal of this clinical trial is to learn about the safety of CAP-002 gene therapy in children with Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy. It will also provide information about whether CAP-002 demonstrates efficacy in treating children with STXBP1 with and without seizures. Participants will have a single infusion of CAP-002, visit the clinic regularly for 2 years for checkups and tests and have seizures recorded in a diary by their caregiver.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:18 - 7

      Key Eligibility Criteria

      Disqualifiers:Gene Therapy History, Prematurity, Others
      Must Not Be Taking:Antisense Oligonucleotides, Corticosteroids

      12 Participants Needed

      Phenylbutyrate for Neurodevelopmental Disorders

      New York, New York
      This trial is testing glycerol phenylbutyrate, a medication that helps brain proteins work better, in children with severe genetic epilepsy and developmental delays. The goal is to see if it is safe and effective for these children.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Early Phase 1
      Age:0 - 17

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Beta Oxidation Errors, Others
      Must Not Be Taking:Alfentanil, Quinidine, Cyclosporine, Probenecid

      50 Participants Needed

      PRAX-222 for Epileptic Encephalopathy

      Memphis, Tennessee
      The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:2 - 18

      Key Eligibility Criteria

      Disqualifiers:Other Genetic Variants, Others
      Must Not Be Taking:Sodium Channel Blockers

      60 Participants Needed

      Brain Stimulation for Epilepsy

      Rochester, Minnesota
      The purpose of this research is to see to what extent electrical stimulation applied to the scalp (transcranial direct current stimulation or tDCS) can reduce the number and intensity of epileptic seizures.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:6+

      Key Eligibility Criteria

      Disqualifiers:Psychogenic Seizures, Psychiatric Hospitalization, Others
      Must Be Taking:Anti-seizure Medicines

      30 Participants Needed

      Ketogenic Diet for Infantile Spasms

      Boston, Massachusetts
      Epileptic spasms (ES) are a predominantly infantile seizure type observed frequently in certain genetic disorders. Ketogenic diet (high ratio of fat to carbohydrate/protein) is an established non-medication treatment for difficult to control seizures, including ES. Because ES are associated with worse developmental and cognitive outcomes if not detected or treated quickly and effectively, this trial aims to test the ketogenic diet to prevent ES in this high-risk population. This trial is a single-center pilot study of 10 infants with genetic seizure disorders to establish if the protocol of early ketogenic diet administration and ES evaluation is safe and feasible.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:0 - 9

      Key Eligibility Criteria

      Disqualifiers:Epileptic Spasms, Cortical Malformation, Others
      Must Be Taking:Ketogenic Diet

      10 Participants Needed

      Why Other Patients Applied

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Epileptic Encephalopathy Trial

      TSHA-105 for SLC13A5 Deficiency

      Dallas, Texas
      Phase 1/2, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of TSHA-105 in individuals with SLC13A5 Citrate Transporter Disorder
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2
      Age:2 - 20

      Key Eligibility Criteria

      Disqualifiers:Bleeding Disorder, Active Infection, Others
      Must Not Be Taking:Immune Suppressants

      2 Participants Needed

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Epileptic Encephalopathy clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Epileptic Encephalopathy clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Epileptic Encephalopathy trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Epileptic Encephalopathy is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Epileptic Encephalopathy medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Epileptic Encephalopathy clinical trials?

      Most recently, we added Pediatric Palliative Care for Rare Diseases, TSHA-105 for SLC13A5 Deficiency and Elsunersen for Epileptic Encephalopathy to the Power online platform.